Helpline
Who are you and what do you do?
At Nutricia, we believe in the power of nutrition to make a positive difference to health.
With scientific research and evidence-based discoveries at the heart of the business, Nutricia offers innovative nutritional solutions that positively impact the health of people with specific nutritional needs. Every day, millions of people rely on Nutricia’s nutritional solutions to live life to its fullest.
With over 120 years of nutritional discoveries and over 600+ publications within allergy, we are proud to offer a unique and comprehensive range of hypoallergenic formulas for every Cow’s Milk Allergy need. Our range of extensively hydrolysed and amino acid formulas provide solutions for all cow’s milk allergic infants, from mild to severe and from birth up to 10 years.
Improving maternal and infant nutrition and health is a shared objective between Nutricia, the WHO, UNICEF and many other stakeholders. Breastfeeding is the best source of nutrition for infants, and we remain dedicated to ensuring parents are empowered with accurate information on nutritional choices and always feel supported.
Our products
The SYNEO range includes an extensively hydrolysed formula – Aptamil Pepti Syneo – and an amino acid formula – Neocate Syneo. They contain a unique blend of prebiotic oligosaccharides and probiotic bacteria, to rebalance the gut microbiota to bring it closer to that of healthy breastfed infants 1-6.
Aptamil Pepti 1 and 2 are an age-adapted range of extensively hydrolysed formulas for infants with mild to moderate CMA.
Neocate LCP, Neocate Junior and Neocate Spoon are an age-adapted range of amino acid-based formulas for infants with moderate to severe CMA.
Important Notice: Breastfeeding is best. Aptamil Pepti and Neocate are foods for special medical purposes and should only be used under medical supervision, after full consideration of the feeding options including breastfeeding. May be suitable for use as the sole source of nutrition for infants from different ages, and / or as part of a balanced diet from 6 months onwards. Refer to label for details. For a full list of details including contraindications please visit Nutricia.co.uk.
What are your business objectives with regards to allergy and supporting people with allergic disease?
At Nutricia, our mission is to provide the best nutritional care to cow’s milk allergic patients, to aid healthcare professionals’ educational development and to invest in helping patients through scientific research. Our investment in pioneering science informs and educates healthcare professionals on the latest advances in the field of cow’s milk allergy and infant feeding.professionals on the latest advances in the field of cow’s milk allergy and infant feeding.
Why have you chosen to partner with Allergy UK?
We understand how serious living with an allergy can be. We are proud to partner with Allergy UK to invest in healthcare professionals’ continued educational development and to support the wider Allergy UK strategy. This includes providing funding for parent/carer resources to help them better understand and manage allergic conditions.
What is the overall objective of the partnership?
Nutricia are proud to help Allergy UK achieve its educational mission through the development of a range of educational services, events and materials. In particular, we are proud to support the Allergy UK Dietetic service which provides expert care at the time of need to those living with food allergies and support to their parents/carers.
Our B Corp Promise
As a Danone brand, Nutricia is a certified B Corp organisation meaning we meet the highest standard of verified social and environmental performance. This way of operating is part of Danone’s DNA and our commitment to driving health through food.
References: 1. Candy, et al. Pediatr Res. 2018;83(3):677–686. 2. Fox, et al. Clin Transl Allergy. 2019;9(1):5. 3. Sorensen et al. Nutrients. 2021; 13:935. 4. Van der Aa, et al. Clin Exp Allergy. 2010;40:765–804. 5. Chua, et al. J Pediatr Gastroenterol Nutr. 2017;65(1):102–106 6. Hubbard et al. Immun Inflamm Dis. 2022;10:e636.